移植片対宿主病（GvHD）市場予測2034：臨床試験、疫学、新興治療法、FDA/EMA/PMDA承認、収益予測、主要企業

DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast – 2034" report delivers an in-depth understanding of Graft Versus Host Disease, including historical and projected epidemiological trends alongside comprehensive GvHD market dynamics across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The GvHD market report outlines current treatment practices, emerging investigational therapies, individual therapy market share, and current and forecasted market size spanning 2020 to 2034 across seven major markets. The report further evaluates current treatment algorithms, key market drivers and barriers, and critical unmet medical needs to identify the most promising opportunities and assess the underlying growth potential of the GvHD market.

Request for a Free Sample Report @ Graft Versus Host Disease (GvHD) Market Forecast

Key Facts from the Graft Versus Host Disease (GvHD) Market Report

• According to DelveInsight's analysis, the GvHD market size is anticipated to grow at a significant CAGR through 2034.
• The Graft versus Host Disease market size in the United States stood at approximately USD 1.1 billion in 2023.
• Leading GvHD companies actively advancing treatments include Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceuticals, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, AltruBio, CSL Behring, Incyte Corporation, Takeda, OncoImmune, Merck (MSD), Regimmune Corporation, Jazz Pharmaceuticals, Millennium Pharmaceuticals, Takeda Oncology, Roche, Genentech, Bristol-Myers Squibb, Xenikos, Synthetic Biologics, Equillium/Biocon, CTI BioPharma, Novartis, GlaxoSmithKline, and others.
• Key GvHD therapies anticipated to enter the market include ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), Jakafi (Ruxolitinib), Temcell (Ryoncil; Remestemcel-L; Prochymal), Obnitix (MC0518), MaaT013, Leukotac (Inolimomab), KD025 (Belumosudil), Itacitinib, and numerous others.

Recent Milestone Developments in GvHD

• April 2025: The California Institute for Regenerative Medicine (CIRM) awarded $8 million to biotech firm Tr1X to advance its Phase I/IIa clinical trial of TRX103—an allogeneic, engineered type 1 regulatory (Tr1) Treg cell therapy designed to prevent graft-versus-host disease in blood cancer patients undergoing mismatched stem cell transplants, with the goal of reducing transplant-related complications and improving patient outcomes.
• March 2025: Orca Bio reported that its investigational T-cell immunotherapy for blood cancers more than doubled the rate of patients remaining free from moderate-to-severe chronic GvHD. Phase III Precision-T trial (NCT05316701) results showed that 78% of patients treated with Orca-T (TRGFT-201) were GvHD-free at one year, compared to just 38% in the standard allogeneic stem cell transplant cohort.
• January 2025: MaaT Pharma (EURONEXT: MAAT) announced positive topline results from its pivotal Phase 3 ARES trial evaluating MaaT013 in patients with acute gastrointestinal GvHD (GI-aGvHD) who are steroid-resistant and either refractory or intolerant to ruxolitinib. The trial met its primary endpoint with a 28-day gastrointestinal overall response rate (GI-ORR) of 62%, significantly exceeding the anticipated rate of 38%, as assessed by an Independent Review Committee.
• December 2024: The FDA granted approval to Mesoblast's allogeneic mesenchymal stromal cell therapy, remestemcel-L (brand name: Ryoncil), for treating steroid-refractory acute GvHD in pediatric patients aged two months and older—marking the first FDA-approved MSC-based therapy.
• June 2024: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. presented results from a randomized, open-label, multicenter Phase II clinical trial of Rovadicitinib for the treatment of third-line and subsequent moderate-to-severe chronic GvHD.
• June 2024: Incyte Corporation released findings from a Phase 3 open-label multicenter study evaluating the efficacy, safety, and pharmacokinetics of axatilimab monotherapy in Japanese participants with recurrent or refractory active chronic GvHD after at least two prior lines of systemic therapy.
• June 2024: Sanofi shared results from a randomized, double-blind, multicenter Phase 3 study evaluating belumosudil in combination with corticosteroids versus placebo plus corticosteroids in participants aged 12 years and older with newly diagnosed chronic GvHD.
• January 2024: BioSenic finalized a binding term sheet agreement with Phebra PTY Ltd. for the development of the first oral formulation of arsenic trioxide for chronic GvHD treatment, including a 2% royalty arrangement on worldwide sales and exclusive worldwide territorial rights for the use of OATO in GvHD.
• April 2023: REGiMMUNE Limited and San Fu Biotech entered into a licensing agreement to develop and commercialize RGI2001 for acute GvHD prophylaxis across major Asian markets.

Do you know what the Graft Versus Host Disease (GvHD) market share will be across 7MM by 2034? @ Graft Versus Host Disease (GvHD) Treatment Market

Graft Versus Host Disease (GvHD) Disease Overview

Graft-versus-host disease (GvHD) is a potentially life-threatening complication that can develop following allogeneic stem cell or bone marrow transplantation, in which donated immune cells (the graft) mount an immune response against the recipient's (host's) tissues, recognizing them as foreign.

GvHD is broadly classified into two distinct forms:

• Acute GvHD typically manifests within the first 100 days post-transplant and predominantly targets the skin, liver, and gastrointestinal tract. Clinical presentations include skin rash, jaundice, hepatic dysfunction, nausea, vomiting, and diarrhea.
• Chronic GvHD can develop at any point following transplantation and presents with more extensive, persistent symptoms potentially affecting multiple organ systems, including the skin, liver, eyes, oral mucosa, lungs, and digestive tract.

Disease severity ranges from mild to life-threatening. Current management relies on immunosuppressive agents, primarily corticosteroids, to modulate the donor immune response and minimize tissue damage. Prophylactic strategies—including immunosuppressant administration and meticulous donor-recipient tissue matching—remain critical in reducing GvHD incidence and severity.

Active research continues to focus on enhancing prevention protocols, elucidating underlying immunological mechanisms, and developing targeted therapies to improve post-transplant patient outcomes and quality of life.

Graft Versus Host Disease (GvHD) Market Analysis

The GvHD market outlook section of the report constructs a detailed understanding of historical, current, and projected market trends by evaluating the impact of current therapies, identifying unmet needs, and analyzing drivers, barriers, and demand for advanced treatment technologies.

This segment provides a thorough assessment of each marketed drug and late-stage pipeline therapy, evaluating their market impact based on annual treatment costs, inclusion and exclusion criteria, mechanism of action, patient compliance rates, expanding market demand, growing patient populations, targeted patient segments, anticipated launch timelines, competitive positioning against existing therapies, brand equity, and key opinion leader perspectives. All calculated market data are presented through clear tables and graphs for immediate comprehension.

According to DelveInsight, the GvHD market across 7MM is projected to undergo substantial transformation during the 2020–2034 study period.

Graft Versus Host Disease (GvHD) Epidemiology

The epidemiology section delivers insights into historical and current GvHD patient populations alongside forecasted trends across seven individual major markets. It explores the drivers behind current and anticipated trends through analysis of multiple studies and expert key opinion leader perspectives, while also providing diagnosed patient pool data, trend analyses, and underlying assumptions.

Interested to know how emerging diagnostic approaches will contribute to increased GvHD diagnosed prevalence? Download the report @ Graft Versus Host Disease (GvHD) Prevalence

Graft Versus Host Disease (GvHD) Drug Uptake Analysis

This section examines the adoption rates of potential GvHD therapies recently launched or anticipated to enter the market between 2020 and 2034. The analysis encompasses market uptake by individual drugs, patient uptake by therapeutic category, and revenue performance for each treatment.

The drug uptake analysis identifies therapies demonstrating the most rapid market adoption, explores the factors driving preferential use of new agents, and enables direct comparison of drugs based on market share and market size—providing critical intelligence for financial planning and regulatory decision-making.

Graft Versus Host Disease (GvHD) Pipeline Development Activities

The report provides detailed insights into therapeutic candidates across Phase II and Phase III clinical development stages, along with analysis of key companies driving targeted therapeutic innovation. Emerging GvHD drugs under clinical investigation include:

• ABSK021 – Abbisko Therapeutics
• SYN-004 – Theriva Biologics
• SER-155 – Seres Therapeutics
• CB103 – Cellestia Biotech
• Glasdegib – Pfizer
• TQ 05105 – Chia Tai Tianqing Pharmaceutical
• RGI-2001 – Regimmune Corporation
• Axatilimab – Syndax Pharmaceuticals
• MaaT013 – MaaT Pharma
• MC 0518 – Medac
• Itolizumab – Equillium
• Elranatamab – Pfizer
• Felzartamab – Janssen Pharmaceutical
• T-Guard – Xenikos

Download the report to discover which TOP 3 therapies will capture the largest GvHD market share by 2034 @ Graft Versus Host Disease (GvHD) Market Outlook

Graft Versus Host Disease (GvHD) Therapeutics Assessment

Major pharmaceutical and biotechnology companies proactively developing novel GvHD therapies that are expected to shape the treatment market in the coming years include:

AstraZeneca (LSE: AZN), Biogen (NASDAQ: BIIB), Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE), CSL Behring (ASX: CSL), Incyte Corporation (NASDAQ: INCY), Takeda (TYO: 4502), Merck & Co., Inc. (NYSE: MRK), Jazz Pharmaceuticals (NASDAQ: JAZZ), Roche (SWX: ROG), Bristol-Myers Squibb (NYSE: BMY), CTI BioPharma (NASDAQ: CTIC), Novartis (SWX: NOVN), GlaxoSmithKline (LSE: GSK), Equillium (NASDAQ: EQ), Biocon (NSE: BIOCON), Syndax Pharmaceuticals (NASDAQ: SNDX), Kadmon Corporation, Medac, MaaT Pharma (EPA: MAAT), ElsaLys Biotech (subsidiary of Mediolanum Farmaceutici Spa), AltruBio, OncoImmune (acquired by Merck & Co., Inc.), Regimmune Corporation, Millennium Pharmaceuticals (acquired by Takeda), Takeda Oncology, Genentech (subsidiary of Roche), Xenikos, Synthetic Biologics (NYSE American: SYN), and others.

Do you know how JAKAVI/JAKAFI (ruxolitinib) and IMBRUVICA (ibrutinib) market launches will impact the GvHD market CAGR? Download the sample report @ Graft Versus Host Disease (GvHD) Market by Therapies

Report Key Insights

1. Graft Versus Host Disease (GvHD) Patient Population
2. GvHD Market Size and Trends
3. Key Cross Competition in the GvHD Market
4. GvHD Market Dynamics (Key Drivers and Barriers)
5. GvHD Market Opportunities
6. GvHD Therapeutic Approaches
7. GvHD Pipeline Analysis
8. GvHD Current Treatment Practices and Algorithms
9. Impact of Emerging Therapies on the GvHD Market

Table of Contents

1. Key Insights
2. Executive Summary
3. Graft Versus Host Disease (GvHD) Competitive Intelligence Analysis
4. GvHD Market Overview at a Glance
5. GvHD Disease Background and Overview
6. GvHD Patient Journey
7. GvHD Epidemiology and Patient Population
8. GvHD Treatment Algorithm, Current Treatment, and Medical Practices
9. GvHD Unmet Needs
10. Key Endpoints of GvHD Treatment
11. GvHD Marketed Products
12. GvHD Emerging Therapies
13. GvHD Seven Major Market Analysis
14. Attribute Analysis
15. GvHD Market Outlook (7 Major Markets)
16. GvHD Access and Reimbursement Overview
17. KOL Views on the GvHD Market
18. GvHD Market Drivers
19. GvHD Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Related Reports 

Graft versus host disease (GvHD) Pipeline Insight

Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK, and Amgen among others.

About DelveInsight

DelveInsight is a premier healthcare-focused market research and consulting firm committed to delivering superior market intelligence and strategic analysis for well-informed business decisions. Backed by a team of seasoned industry specialists with extensive expertise across the life sciences and healthcare sectors, DelveInsight provides customized research solutions and actionable insights to organizations worldwide. Connect with us to access high-quality, accurate, and real-time intelligence that positions you ahead of the growth curve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Kanishk Kumar

Email: kkumar@delveinsight.com 

Phone: 09650213330

Address: 304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/